Home | The Oncologist Community

From the Editor: Twenty-Five Years of The Oncologist

Bruce A. Chabner, The Oncologist

As The Oncologist marks a milestone year, its 25th anniversary, we reflect on our good fortune to have been witnesses and participants in the remarkable expansion of oncological practice over the past quarter century, as molecular oncology and immunotherapy have changed cancer care. Our hope is that The Oncologist has been a worthwhile effort, and we give special thanks to our authors, readers, and dedicated staff.

*In celebration of our 25th anniversary we are pleased to provide all readers free access to all content.

Immune-Related Adverse Events

Immunotherapy enhances a cancer patient’s immune system to fight an array of cancers. Immune checkpoint blockade can, however, induce inflammatory side effects known as immune-related Adverse Events (irAE). Because these rare but serious complications need to be quickly detected and properly treated, The Oncologist is devoting a new series designed to enhance the care of patients who may well benefit from therapeutic strategies that involve one or more these powerful immunotherapies.

PMC: Molecular Tumor Board

Precision Medicine Clinic: Molecular Tumor Board is a case-based series designed to help clinicians optimize molecular testing for their patients. The Editors of The Oncologist encourage institutions to share their findings and experiences to help improve the precision of genomic oncology and fulfill its promise of improved outcomes for patients. This collection highlights a diverse set of patients exhibiting a range of tumor types and mutations.

Cancer Care & the Opioid Crisis

Opioids form the cornerstone of pain management in cancer patients, but the crisis of opioid addiction has resulted in significant challenges facing patients, physicians, lawmakers, and communities across the nation. This series is focused to help clinicians manage the opioid crisis while ensuring adequate pain management for their patients.

	01/02/20	Celebrating Twenty-Five Years of The Oncologist
	12/19/19	irAEs Predict Durable Efficacy Even in Responders
	12/10/19	December Issue Table of Contents Alert
	12/05/19	Malnutrition in Phase I and II Trial Patients

Highlighted Article

From the Editor: Twenty-Five Years of The Oncologist

Immune-Related Adverse Events

PMC: Molecular Tumor Board

Cancer Care & the Opioid Crisis